{"id":2307,"date":"2026-03-11T15:10:26","date_gmt":"2026-03-11T07:10:26","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&#038;p=2307"},"modified":"2026-03-25T11:59:05","modified_gmt":"2026-03-25T03:59:05","slug":"podcast-launch-innovations-in-immuno-oncology","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/podcast-launch-innovations-in-immuno-oncology\/","title":{"rendered":"Podcast Launch: Innovations in Immuno-Oncology"},"content":{"rendered":"<h2 data-start=\"54\" data-end=\"312\">Podcast Launch: Innovations in Immuno-Oncology<\/h2>\n<p data-start=\"54\" data-end=\"312\">HanchorBio&#8217;s new and original podcast series, <em data-start=\"107\" data-end=\"139\">Innovations in Immuno-Oncology<\/em>, offer listeners a closer look at the scientific rationale, business strategy, and global licensing perspectives behind next-generation immuno-oncology drug development.<\/p>\n<p data-start=\"54\" data-end=\"312\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-2312 aligncenter\" src=\"https:\/\/www.hanchorbio.com\/wp-content\/uploads\/\u6f22\u5eb7\u8b80\u61c2\u816b\u7624\u514d\u75ab\u65b0\u85e5\u7684\u6297\u764c\u9769\u547d-1.jpg\" alt=\"HanchorBio-Podcast-innovations-in immuno-oncology\" width=\"389\" height=\"389\" srcset=\"https:\/\/www.hanchorbio.com\/wp-content\/uploads\/\u6f22\u5eb7\u8b80\u61c2\u816b\u7624\u514d\u75ab\u65b0\u85e5\u7684\u6297\u764c\u9769\u547d-1.jpg 3000w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/\u6f22\u5eb7\u8b80\u61c2\u816b\u7624\u514d\u75ab\u65b0\u85e5\u7684\u6297\u764c\u9769\u547d-1-300x300.jpg 300w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/\u6f22\u5eb7\u8b80\u61c2\u816b\u7624\u514d\u75ab\u65b0\u85e5\u7684\u6297\u764c\u9769\u547d-1-1024x1024.jpg 1024w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/\u6f22\u5eb7\u8b80\u61c2\u816b\u7624\u514d\u75ab\u65b0\u85e5\u7684\u6297\u764c\u9769\u547d-1-150x150.jpg 150w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/\u6f22\u5eb7\u8b80\u61c2\u816b\u7624\u514d\u75ab\u65b0\u85e5\u7684\u6297\u764c\u9769\u547d-1-768x768.jpg 768w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/\u6f22\u5eb7\u8b80\u61c2\u816b\u7624\u514d\u75ab\u65b0\u85e5\u7684\u6297\u764c\u9769\u547d-1-1536x1536.jpg 1536w, https:\/\/www.hanchorbio.com\/wp-content\/uploads\/\u6f22\u5eb7\u8b80\u61c2\u816b\u7624\u514d\u75ab\u65b0\u85e5\u7684\u6297\u764c\u9769\u547d-1-2048x2048.jpg 2048w\" sizes=\"auto, (max-width: 389px) 100vw, 389px\" \/><\/p>\n<p data-start=\"314\" data-end=\"1050\">The podcast highlights the core of HanchorBio\u2019s R&amp;D efforts and brings together company leaders and experts to share frontline insights on how clinical data, platform technologies, and licensing validation can unlock broader global market potential. Topics span tumor immunology, product design strategy, international business development, and practical lessons from the path between the laboratory and the global partnering table. Featured guests to date include founder Dr. Scott Liu, Chief Business Officer Dr. YueHua Cong, Vice President of R&amp;D Dr. Chi-Ling Tseng, and Executive Director of CMC Process Development Dr.\u00a0 Vivian Kuo, each offering a distinct perspective on HanchorBio\u2019s innovation strategy in immuno-oncology.<\/p>\n<p data-start=\"1052\" data-end=\"1223\">Listen on:<br data-start=\"1062\" data-end=\"1065\" \/>Apple Podcast: <a class=\"decorated-link\" href=\"https:\/\/reurl.cc\/Zl6RMl\" target=\"_new\" rel=\"noopener\" data-start=\"1080\" data-end=\"1103\">https:\/\/reurl.cc\/Zl6RMl<\/a><br data-start=\"1103\" data-end=\"1106\" \/>Spotify: <a class=\"decorated-link\" href=\"https:\/\/reurl.cc\/KOayvy\" target=\"_new\" rel=\"noopener\" data-start=\"1115\" data-end=\"1138\">https:\/\/reurl.cc\/KOayvy<\/a><br data-start=\"1138\" data-end=\"1141\" \/>Or search for <strong><em data-start=\"1155\" data-end=\"1187\">Innovations in Immuno-Oncology<\/em><\/strong> on your preferred podcast platform.<\/p>\n<p data-start=\"1225\" data-end=\"1247\"><strong data-start=\"1225\" data-end=\"1247\">Available Episodes<\/strong><\/p>\n<p data-pm-slice=\"0 0 []\"><strong>EP1 | The Game in IO<\/strong><\/p>\n<p>A discussion on the long-term strategic value of immuno-oncology innovation and next-generation cancer therapeutics.<\/p>\n<p><strong>EP2 | How HanchorBio is Scaling Global Cancer Immunotherapy<\/strong><\/p>\n<p>A closer look at the HCB101 regional licensing case and HanchorBio\u2019s path<\/p>\n<p><strong>EP3 | Decoding the Business Moat of HCB101<\/strong><\/p>\n<p>An exploration of the scientific foundations of immuno-oncology and how innovative biologics may reshape cancer treatment strategies.<\/p>\n<p><strong>EP4 | The 1.6% Challenge<\/strong><\/p>\n<p>An introduction to HanchorBio\u2019s FBDB\u2122 platform and the design principles behind next-generation trifunctional fusion proteins.<\/p>\n<p><strong>EP5 | The 1.6% Frontier<\/strong><\/p>\n<p>A deep dive into the design logic of HCB301 and the strategic vision behind trifunctional immunotherapy.<\/p>\n<p><strong>EP6 | The CMC Moat<\/strong><\/p>\n<p>An inside look at why CMC is more than manufacturing, and how process development, quality control, and scalability form a critical moat in turning a promising molecule into a global medicine.<\/p>\n<p><strong>EP7 | Disrupting a $4B Market: Triple-Combo Cancer Strategy<\/strong><\/p>\n<p>A deep dive into the recently disclosed, astonishing clinical data for HCB101 and explains how HanchorBio is navigating global translational medicine with world-class standards.<\/p>\n<p><strong>EP8 |\u00a0From Burn to Cash Flow: Hanchor\u2019s Turning Point<\/strong><\/p>\n<p>To break down how the company is building a sustainable cash flow engine while navigating the intense demands of biotech R&amp;D.<\/p>\n<p data-start=\"1858\" data-end=\"1909\">More episodes will be released on an ongoing basis.<\/p>\n<p data-start=\"1911\" data-end=\"2469\" data-is-last-node=\"\" data-is-only-node=\"\"><strong>Disclaimer<\/strong><\/p>\n<p data-start=\"1911\" data-end=\"2469\" data-is-last-node=\"\" data-is-only-node=\"\">This podcast is intended to help listeners better understand biotechnology industry trends and HanchorBio\u2019s core value through scientific interpretation and business insight. All clinical data referenced are subject to the Company\u2019s official public disclosures. The content does not constitute investment advice of any kind. Any discussion of product potential, technology development, or market opportunity reflects industry experience and professional analysis, and should not be interpreted as a guarantee of future share price, revenue, or profitability.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HanchorBio&#8217;s new and original podcast series, Innovations in Immuno-Oncology, offer listeners a closer look at the scientific rationale, business strategy, and global licensing perspectives behind next-generation immuno-oncology drug development.<\/p>\n","protected":false},"featured_media":2312,"template":"","news-category":[35,36,37],"class_list":["post-2307","news","type-news","status-publish","has-post-thumbnail","hentry","news-category-awards","news-category-events","news-category-market-and-licensing"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/2312"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2307"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}